Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier

Bioconjugate Chemistry

Volumn 19, Issue 11, 2008, Pages 2182-2188

  Kang, Hyunmin ^a   Alam, Md Rowshon ^a   Dixit, Vidula ^a   Fisher, Michael ^a   Juliano, Rudy L ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; CELLS; CYTOLOGY; FLUORESCENCE MICROSCOPY; OLIGONUCLEOTIDES;

ANTISENSE; ANTISENSE OLIGONUCLEOTIDES; BIO-CONJUGATION; CELLULAR DELIVERY; INTEGRINS; PHARMACOLOGICAL EFFECTS; PROTEIN CARRIER; TARGETED DELIVERY; TARGETED PROTEINS; TEST SYSTEMS;

POLYETHYLENE GLYCOLS;

ANTISENSE OLIGONUCLEOTIDE; ARGINYLGLYCYLASPARTIC ACID; CARRIER PROTEIN; CYSTEINE; INTEGRIN; LUCIFERASE; MACROGOL; SERUM ALBUMIN; SULFUR; VITRONECTIN RECEPTOR;

ARTICLE; BIOLOGICAL ACTIVITY; CELL NUCLEUS; CELL TRANSPORT; CHEMICAL BOND; CONFOCAL MICROSCOPY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; PROTEIN TARGETING; REPORTER GENE;

EID: 56749104670     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc800270w     Document Type: Article

References (36)

1. Chan, J. H., Lim, S., and Wong, W. S. (2006) Antisense oligonucleotides: from design to therapeutic application. Clin. Exp. Pharmacol. Physiol. 33, 533-40.
2. de Fougerolles, A., Vornlocher, H. P., Maraganore, J., and Lieberman, J. (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discovery 6, 443-53.
3. Crooke, S. T. (2004) Progress in antisense technology. Annu. Rev. Med. 55, 61-95.
4. Kim, D. H., and Rossi, J. J. (2007) Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8, 173-84.
5. Mescalchin, A., Detzer, A., Wecke, M., Overhoff, M., Wunsche, W., and Sczakiel, G. (2007) Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: novel options by phosphorothioate-stimulated delivery. Exp. Opin. Biol. Ther. 7, 1531-8.
6. Russ, V., and Wagner, E. (2007) Cell and tissue targeting of nucleic acids for cancer gene therapy. Pharm. Res. 24, 1047-57.
7. Derfus, A. M., Chen, A. A., Min, D. H., Ruoslahti, E., and Bhatia, S. N. (2007) Targeted quantum dot conjugates for siRNA delivery. Bioconjugate Chem. 18, 1391-6.
8. Fattal, E., Couvreur, P., and Dubernet, C. (2004) "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive uposomes. Adv. Drug Delivery Rev. 56, 931-46.
9. Gilmore, I. R., Fox, S. P., Hollins, A. J., and Akhtar, S. (2006) Delivery strategies for siRNA-mediated gene silencing. Curr. Drug Delivery 3, 147-5.
10. Li, W., and Szoka, F. C., Jr. (2007) Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res. 24, 438-49.
11. Sanguino, A., Lopez-Berestein, G., and Sood, A. K. (2008) Strategies for in vivo siRNA delivery in cancer. Mini Rev. Med. Chem. 8, 248-55.
12. Vinogradov, S. V., Batrakova, E. V., and Kabanov, A. V. (2004) Nanogels for oligonucleotide delivery to the brain. Bioconjugate Chem. 15, 50-60.
13. Abes, S., Moulton, H., Turner, J., Clair, P., Richard, J. P., Iversen, P., Gait, M. J., and Lebleu, B. (2007) Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splice-correcting oligonucleotides. Biochem. Soc. Trans. 35, 53-5.
14. Juliano, R. L. (2005) Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA. Curr. Opin. Mol. Ther. 7, 132-6.
15. Alam, M. R., Dixit, V., Kang, H., Li, Z. B., Chen, X., Trejo, J., Fisher, M., and Juliano, R. L. (2008) Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res. 36, 2764-76.
16. Cesarone, G., Edupuganti, O. P., Chen, C. P., and Wickstrom, E. (2007) Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant 1RS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1. Bioconjugate Chem. 18, 1831-40.
17. Jain, R. K. (1999) Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1, 241-63.
18. Rippe, B., Rosengren, B. I., Carlsson, O., and Venturoli, D. (2002) Transendothelial transport: the vesicle controversy. J. Vasc. Res. 39, 375-90.
19. Scherphof G. L. (1991) In vivo behavior of liposomes; interaction with the mononuclear phagocyte system and implications for drug targeting, In Targeted Drug Delivery (Juliano, R. L. Ed.), Springer Verlag, Berlin.
20. Aderem, A., and Underhill, D. M. (1999) Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 17, 593-623.
21. van Vlerken, L. E., Vyas, T. K., and Amiji, M. M. (2007) Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 24, 1405-14.
22. Agrawal, S., and Zhang, R. (1997) Pharmacokinetics of oligonucleotides. Ciba Found Symp. 209, 60-75, discussion 75-8.
23. Cossum, P. A., Sasmor, H., Dellinger, D., Truong, L., Cummins, L., Owens, S. R., Markham, P. M., Shea, J. P., and Crooke, S. (1993) Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267, 1181-90.
24. DeLong, R. K., Nolting, A., Fisher, M., Chen, Q., Wickstrom, E., Kligshteyn, M., Demirdji, S., Caruthers, M., and Juliano, R. L. (1997) Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. Antisense Nucleic Acid Drug Dev. 7, 71-7.
25. Amantana, A., Moulton, H. M., Cate, M. L., Reddy, M. T., Whitehead, T., Hassinger, J. N., Youngblood, D. S., and Iversen, P. L. (2007) Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjugate Chem. 18, 1325-31.
26. Stupack, D. G., and Cheresh, D. A. (2004) Integrins and angiogenesis. Curr. Top. Dev. Biol. 64, 207-38.
27. Sazani, P., and Kole, R. (2003) Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J. Clin. Invest. 112, 481-6.
28. Di Stefano, G., Fiume, L., Baglioni, M., Busi, C., Bolondi, L., Farina, C., Mori, F., Chieco, P., Pariali, M., Kratz, F., Molin, L., Salmaso, S., and Cahceti, P. (2008) Doxorubicin coupled to lactosaminated albumin: effect of heterogeneity in drug load on conjugate disposition and hepatocellular carcinoma uptake in rats. Eur. J. Pharm. Sci. 33, 191-8.
29. Temming, K., Meyer, D. L., Zabinski, R., Senter, P. D., Poelstra, K., Molema, G., and Kok, R. J. (2007) Improved efficacy of αvβ3-targeted albumin conjugates by conjugation of a novel auristatin derivative. Mol. Pharm. 4, 686-94.
30. Kirkham, M., and Parton, R. G. (2005) Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. Biochim. Biophys. Acta 1745, 273-86.
31. Caswell, P. T., and Norman, J. C. (2006) Integrin trafficking and the control of cell migration. Traffic 7, 14-21.
32. White, D. P., Caswell, P. T., and Norman, J. C. (2007) αvβ3 and α5β1 integrin recychng pathways dictate downstream Rho kinase signaling to regulate persistent cell migration. J. Cell Biol. 177, 515-25.
33. Ryan, S. M., Mantovani, G., Wang, X., Haddleton, D. M., and Brayden, D. J. (2008) Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin. Drug Delivery 5, 371-83.
34. Lv, H., Zhang, S., Wang, B., Cui, S., and Yan, J. (2006) Toxicity of cationic lipids and cationic polymers in gene delivery. J. Controlled Release 114, 100-9.
35. Juliano, R. L. (2007) Biological Barriers to Nanocarrier-Mediated Delivery of Therapeutic and Imaging Agents, In Nanobiotechnology II (Mirkin, C., and Niemeyer, C. Eds.) pp 263-278, Wiley-VCH, Weinheim, Germany.
36. Greish, K. (2007) Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Targeting 15, 457-64.